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ABSTRACT Uptake of system L amino acid substrates
into isolated placental plasma membrane vesicles in the
absence of opposing side amino acid (zero-trans uptake) is
incompatible with the concept of obligatory exchange,
where inﬂux of amino acid is coupled to efﬂux. We
therefore hypothesized that systemL amino acid exchange
transporters are not fully obligatory and/or that amino
acids are initially present inside the vesicles. To address
this, we combined computational modeling with vesicle
transport assays and transporter localization studies to
investigate the mechanisms mediating [14C]L-serine (a
system L substrate) transport into human placental mi-
crovillous plasma membrane (MVM) vesicles. The carrier
model provided a quantitative framework to test the 2 hy-
potheses that L-serine transport occurs by either obligate
exchangeornonobligateexchangecoupledwithfacilitated
transport (mixed transport model). The computational
model could only account for experimental [14C]L-serine
uptake data when the transporter was not exclusively in
exchange mode, best described by the mixed transport
model. MVM vesicle isolates contained endogenous
amino acids allowing for potential contribution to zero-
trans uptake. Both L-type amino acid transporter (LAT)
1 and LAT2 subtypes of system L were distributed to
MVM, with L-serine transport attributed to LAT2. These
ﬁndings suggest that exchange transporters do not
function exclusively as obligate exchangers.—Widdows,
K. L., Panitchob, N., Crocker, I. P., Please, C. P., Hanson,
M. A., Sibley, C. P., Johnstone, E. D., Sengers, B. G., Lewis,
R.M.,Glazier, J. D. Integration of computationalmodeling
with membrane transport studies reveals new insights into
amino acid exchange transport mechanisms. FASEB J.
29, 2583–2594 (2015). www.fasebj.org
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TRANSPORT OF AMINO ACIDS ACROSS an epithelium is a com-
plex process mediated by a broad array of amino acid
transporters expressed in the plasma membrane (1, 2).
These various transport proteins are classiﬁed according
to their transport mechanism (2, 3). Accumulative trans-
porters mediate transport of amino acids against an amino
acid concentration gradient using secondary active trans-
port dependent on electrochemical gradients. Obligate
exchangers (antiporters) transfer one extracellular amino
acid in exchange for an intracellular amino acid, whereas
facilitated transporters (uniporters) enable facilitated diffu-
sion down the prevailing amino acid concentration gradient
(4, 5).The interactionof all 3mechanisms is required fornet
directional transfer of amino acids across absorptive epi-
thelia such as intestine, kidney, and placenta (5, 6).
Although these systems have been characterized at the
molecular level (2, 4), their functional coordination and
interaction inmediating transepithelial transport is poorly
deﬁned. We previously applied computational modeling
to construct an integrated amino acid transport model for
several amino acids across the human placental syncytio-
trophoblast as a model epithelium (7). However, a more
mechanistic modeling approach is required to fully un-
derstand the functional roles of the different amino acid
transporters (8). Computational models can therefore
be applied to generate simulations of speciﬁc transport
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mechanisms, and when validated with experimental data,
can provide functional insight into amino acid transport
activity not available through observation alone.
Among the various transport systems, system L is the
principal Na+-independent transport system for providing
cells with neutral amino acids, many of which are nutrition-
ally essential. The 2 L-type amino acid transporters, LAT1
(SLC7A5) and LAT2 (SCL7A8) (9–11), are expressed in a
variety of tissues such as the brain, kidney, gastrointestinal
tract, testis, andplacenta, indicating their key functional role
in cellular growth and amino acid metabolism (12–14).
System L transporters are reported to function as obligate
exchangers, transporting one amino acid across the plasma
membrane in direct exchange for another, thereby altering
the relative composition of amino acids without affecting
net amount (12, 15). Principal evidence for their obligatory
exchange behavior stems from functional studies demon-
strating that trans-stimulation of amino acid uptake can be
induced by amino acid preloading (9, 15–17). However,
there is inconsistency regarding the obligatory nature of the
LAT2 subtype, which has been reported to exhibit a facili-
tated transport component (18, 19). This is of particular
interest asweandothershavepreviously reported theuptake
of various system L substrates into non-preloaded plasma
membrane vesicles (zero-trans uptake) isolated from the
humanplacenta, which is incompatible with the principal of
obligatory exchange where amino acids are required on
both sides of the plasma membrane (16, 17, 20–22). These
observations therefore led us to hypothesize that system L
amino acid exchange transporters (e.g., LAT2) may not be
fully obligatory as previously thought. Alternatively, endog-
enous aminoacidsmaybe intrinsically present insideplasma
membrane vesicles sufﬁcient to enable obligatory exchange.
To address these hypotheses, we recently developed
a computational amino acid transport model that describes
the possibility for the uptake of L-serine (a LAT2 substrate)
into human placental microvillous plasma membrane
(MVM) vesicles by both obligate exchange andnonobligate
transport mechanisms (i.e., facilitated transport) (Fig. 1A)
(19). However, the previous experiments were unable to
distinguish the extent to which these 2 transport mecha-
nisms played a role. Therefore, our current aim was to de-
sign new experiments to further test the transport model
and generate computational simulations to predict the
transport mechanisms that best describe the uptake of
L-serine intoMVMvesicles. Thebiologic accuracyof the sim-
ulationswas validatedbydetermininghowclosely themodel
predictions for both transport mechanisms ﬁtted the ex-
perimentaldata. Inaddition,we investigated thepresenceof
endogenous amino acids in MVM vesicle isolates and ex-
plored how different exogenous preloaded amino acids
affect L-serine uptake capacity. Finally, we examined the
distribution of the LAT2 protein, and its localization with
respect to LAT1, within the MVM of the human placental
epithelial exchange barrier, the syncytiotrophoblast (SCT).
MATERIALS AND METHODS
Mathematical model of amino acid exchange transporters
We recently described a computational model of system L
transport that speciﬁcally addresses the possibility for obligate
and nonobligate exchange (corresponding to a facilitated
transport component; Fig. 1B) (19). The proposed carrier-
mediated model assumes that amino acid must bind to the
transporter (carrier) to confer transport across the plasma
membrane. Once bound, the transporter can undergo
a conformational change exposing the substrate binding site
to the opposite side of the plasma membrane, thereby per-
mitting translocation.
The obligate exchangemodel assumes bidirectional transport
of amino acids across the plasma membrane with 1:1 stoichiom-
etry, for example., amino acid must be present on both sides of
theplasmamembrane to confer transport (antiport) (Fig. 1B). In
contrast, the transporter can also functionwith varying degrees of
facilitated transport whereby the unidirectional transport of
amino acids across the plasma membrane is driven by the di-
rection of the transmembrane amino acid concentration gradi-
ent. The 2 transport mechanisms are distinguished by the
parameter h, which deﬁnes the relative mobility of the unbound
transporter (i.e., the rate of transition of the unbound transporter
relative to the translocation rate of the bound amino acid-
transporter complex). The case h = 0 corresponds to obligate
exchange, whereas for h. 0, the transporter will display varying
degrees of facilitated transport. Thus, the carrier model was hy-
pothesized to represent a single transporter thatpermits substrate
transport by either (1) obligate exchange or (2) nonobligate
exchange with a facilitated transport component (mixed trans-
port model). Both transport models express net transport as
a functionof transportermobility (translocation rateD), substrate
binding (dissociation constant K), and the concentrations of
amino acid on both sides of the plasma membrane. A detailed
description of the underlying model assumptions and for-
mulations is given in Panitchob et al. (19).
Experimental testing using isolated plasma
membrane vesicles
The 2 hypothesized transport mechanisms were tested experi-
mentally using plasma membrane vesicles isolated from the
maternal-facingMVM of human placenta. This epithelial plasma
membrane can be isolated in relatively pure form and is exten-
sively used to characterize various amino acid transport systems
(23–27). Radiolabeled L-serine was selected as the amino acid
substrate because of its preference for LAT2 over LAT1 (7, 16).
To separate the 2 transport mechanisms mediating L-serine
uptake into MVM vesicles, we developed a speciﬁc set of experi-
mental protocols designed to exploit the underlying transport
characteristics of obligate and facilitated transport, as deﬁned in
the computational model hypotheses (Fig. 1B). Because both
obligate exchangers and facilitated transport phenomena are
intrinsically dependent on the concentration of amino acids on
both sides of the membrane, we measured the uptake of [14C]L-
serine (tracer) into isolated MVM vesicles in response to varia-
tions in intravesicular and extravesicular unlabeled L-serine
concentrations, outlined in the experimental matrix (Fig. 1C).
In essence, these conditions were used to test the capacity of
the exchanger (antiporter) to be trans-stimulated, together with
its ability to act as a facilitated transporter (uniporter) in the
presence of a transmembrane amino acid concentration gradi-
ent. In particular, the 2 transport mechanisms were postulated to
be differentially affected by added L-serine concentrations inside
the MVM vesicles, leading to different concentrations of [14C]L-
serine inside the vesicles at equilibrium. The obligatory exchange
mechanism was predicted to equilibrate buffer composition
through 1:1 bidirectional exchange resulting in the same pro-
portion, but different absolute levels of [14C]L-serine, dependent
on the concentration of L-serine added inside the vesicle. In
contrast, in the case of the mixed transport model, [14C]L-serine
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inﬂux would eventually reach an equilibrium concentration that
would be identical across all experimental conditions.
To test these hypotheses, [14C]L-serine uptake into MVM
vesicles was measured in response to 3 main situations: (1): no
(initial) internal L-serine added yet increasing external L-serine
concentrations (zero-trans experiments 1, 2, and 5)—the in-
wardly directed L-serine gradient is predicted to drive facilitated
transport as there is no initial internal L-serine to drive 1:1
obligatory exchange; (2) constant external L-serine concentra-
tion with increasing internal L-serine concentrations (experi-
ments 2, 3, 4, and 4b)—the outwardly directed L-serine gradient
is predicted to lead to trans-stimulationofexchange; and (3)high
concentrations of external L-serine (experiments 5–7) to study
the comparable effects of trans-stimulation of exchange and
transporter saturation (Fig. 1C).
Preparation of plasma membrane vesicles
Placentas were obtained following written informed consent
with the approval of the Central Manchester Research Ethics
Committee (REC 12/NW/0574) from uncomplicated singleton
pregnancies at term (38–40 wk of gestation) delivered by Cae-
sarean section. MVM vesicles were isolated using Mg2+ pre-
cipitation and differential centrifugation as described previously
(23). The ﬁnal MVM pellet was resuspended in intravesicular
buffer (IVB; 290 mM sucrose, 5 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, and 5 mM Tris, pH 7.4) alone
(experiments 1, 2, and 5) or preloaded with 250 (experiments
3 and 6) or 1000 mM unlabeled L-serine (experiments 4, 4b,
and 7). MVM fragments were vesiculated by passing 15 times
through a 25-gauge needle and stored at 280°C prior to use.
MVM protein concentration was determined using the Lowry
method (28), and purity was assessed by measuring the en-
richment ofMVMalkaline phosphatase activity comparedwith
the placental homogenate (23). MVM vesicles were 21.06 1.4
times enriched compared with initial placental homogenate
(means 6 SEM, n = 9 placentas).
Na+-independent uptake of [14C]L-serine into MVM vesicles
Na+-independent uptake of 7.5 mM [14C]L-serine (tracer;
0.1 mCi/ml; Perkin Elmer, Beaconsﬁeld, Buckinghamshire,
United Kingdom) into MVM vesicles was measured at room
temperature using rapid vacuum ﬁltration (16, 25) correspond-
ing to the conditions set by the experimental matrix (Fig. 1C).
MVM vesicles (diluted to 10 mg/ml protein with IVB) were
equilibrated to room temperature (21–25°C) prior to uptake.
[14C]L-serine uptake was initiated by addition of 20 ml MVM
vesicle suspension to 20 ml extravesicular buffer (5 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, 5 mM Tris, and
145mMKCl, pH 7.4) containing 7.5mM[14C]L-serine without or
with unlabeled L-serine (0, 250, or 1000 mM). For experiments 4
and4b, thehigh intravesicular L-serine concentration (1000mM)
was diluted in either 50 or 380 ml extravesicular buffer to
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Figure 1. Experimental design for modeling system L amino acid transport across the MVM of human placenta. A) Schematic
representation of the mode of system L amino acid transport across MVM comprising a capacity to function both as an obligate
antiporter EX, as well as a facilitated transporter as deﬁned by the carrier model. AI and AII represent tracer amino acid at the
external face of MVM and in the cytoplasmic compartment of the SCT, respectively. B) The computational model was applied to
describe the mixed transport carrier model with exchanger and facilitated transporter capacities as illustrated in A (19). For
obligate exchange, transporter X can bind to either radiolabeled tracer amino acid A or an unlabeled amino acid B to form
a complex AXI or BXI, respectively, which can translocate between the external facing aspect of MVM in direct contact with
maternal blood (MB) to the inside face of MVM in contact with the cytoplasm of SCT, represented as AXII or BXII, respectively.
In contrast, transporter X can also translocate between the external and internal faces unloaded, depending on the parameter h,
which describes the rate at which the unbound transporter (XI or XII) can translocate back across the membrane relative to the
rate of amino acid transporter binding (D). The case h = 0 corresponds to an obligatory exchanger, whereas for h . 0, the
transporter will display unidirectional facilitative transport governed by the direction of the transmembrane amino acid
concentration gradient. C) The computational model was tested experimentally by measuring the Na+-independent uptake of
[14C]L-serine (AI) (tracer) into isolated human placental MVM vesicles in response to various intravesicular (BII) and extra-
vesicular (BI) additions of unlabeled L-serine (Ci) outlined in the experimental matrix in Cii. CT, cytotrophoblast cell; EX/FT,
exchanger/facilitated transporter.
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generate an extravesicular L-serine concentration of 250 or
50 mM, respectively. Uptake was measured at variable time
points up to 10min and stopped by the addition of 2ml ice-cold
Krebs buffer (130 mM NaCl, 10 mM Na2HPO4, 4.2 mM KCl,
1.2 mM MgSO4, and 0.75 mM CaCl2, pH 7.4) and ﬁltered
through a 0.45 mM nitrocellulose ﬁlter under vacuum. Filters
were washed with 10 ml Krebs buffer, and the ﬁlter-associated
radioactivity was determined by liquid scintillation counting.
No protein controls (replacement of MVM vesicle protein by
IVB) were included in parallel to determine tracer binding to
the ﬁlter, which was subtracted from total vesicle count.
Model predictions
Model simulations were generated to predict the uptake of [14C]
L-serine into MVM vesicles under the 8 experimental conditions
according to the obligate exchange and mixed transport model
(Fig. 2A–C). Model parameters were determined from previous
[14C]L-serine uptake kinetics and zero-trans time course
experiments (19). For the obligatory model, h was set to zero,
whereas for the mixed transport model, the relative mobility
of the unbound transporter parameter (h) was chosen to be
0.04, based on a previous report that estimated an upper
conﬁdence interval of 4% for efﬂux by facilitated transport
relative to obligatory exchange (15). Based on this value of h,
a dissociation constant (K) of 1129 mM and ﬁtted value of the
transporter’s effective uptake rate (V) of 92mM/minwerederived
[detailedmodelequationsaregiven inPanitchob et al. (19)].Time
course integration was performed to obtain estimated intra-
vesicular concentrations from the model equation for tracer in-
ﬂux (19). An intravesicular volume of 1.3ml/mg protein was used
to generatemodel predictions, based on themean value obtained
from previous experiments performed under similar buffer con-
ditions (29, 30) (data not shown). All computational simulations
were performed using MATLAB (matrix laboratory; MathWorks,
Natick, MA, USA).
Model ﬁttings
The experimental [14C]L-serine uptake data (picomoles per
milligram protein) were converted to a concentration (micro-
molar) as described above and ﬁtted to the 2 distinct transport
models using a least squares criterion. Three parameters were
ﬁtted for the mixed transport model: (1) the relative mobility of
the unbound transporter h, (2) the effective uptake rate V, and
(3) the dissociation constant K. Similarly, V and K were ﬁtted for
the obligatorymodel; however, in accordance with the obligatory
model assumptions, h was set to zero, and instead a potential
initial concentration of intravesicular L-serine was estimated
that would enable exchange (19). The averaged data (n = 5–9
placentas) for all 8 conditions were ﬁtted simultaneously based
on a single set of parameters, rather than each experiment
separately.
Trans-stimulation of [14C]L-serine uptake by various
intravesicular amino acids
Our initial experiments demonstrated that a steep outwardly di-
rected transmembrane concentration gradient created by addi-
tion of intravesicular L-serine caused substantial trans-stimulation
of 7.5 mM [14C]L-serine inﬂux into MVM vesicles (experiment
4b). To investigate the effect of other substrate amino acids/
analogs, MVM vesicles were preloaded at the time of vesicula-
tion with 1000 mM L-serine, L-alanine, glycine, L-methionine,
L-phenylalanine, L-leucine, 2-aminobicyclo[2.2.1]heptane-2-
carboxylic acid, or D-leucine as potential systemL substrates. In
addition, L-proline and a-methylaminoisobutyric acid (MeAIB)
were included as controls that were not system L substrates,
and mannitol addition served as osmotic control. Uptake of
7.5 mM [14C]L-serine into MVM vesicles was measured as
described above.
Endogenous amino acid concentration in MVM vesicles
To explore the possibility that zero-trans uptake might be
explained by the presence of endogenous amino acids within
MVM vesicles, amino acid concentrations within the vesicle iso-
lates was measured by HPLC following deproteinization with
sulphosalicylic acid.
Cellular localization of LAT2 and LAT1 in human placenta
In linewithourhypothesis forLAT2-mediated L-serineuptake,we
examined the expression of LAT2 and its colocalization with
LAT1 in human term placenta using immunoﬂuorescence. Fro-
zen villous sections (3 mM) were postﬁxed in 10% neutral buff-
ered formalin for 15 minutes. Tissues were permeabilized using
0.5% Triton X-100 diluted in Tris-buffered saline (100 mM Tris
and 150mMNaCl, pH 7.6) for 15 minutes at room temperature.
To minimize autoﬂuorescence, sections were incubated with so-
dium borohydrate (10 mg/ml) diluted in ice-cold Tris-buffered
saline for 33 10minutes at 4°C.Nonspeciﬁc proteinbinding sites
were blocked using 10% normal donkey serum (Dako, Ely,
United Kingdom) diluted in Tris-buffered saline for 30 minutes.
Sections were incubated with either rabbit polyclonal anti-LAT1
(19mg/ml, P00801; Capralogics, Hardwick,MA,USA) for 1 hour
at room temperature (31, 32) or mouse monoclonal anti-LAT2
(20mg/ml, clone8B12; Abcam,Cambridge,UnitedKingdom) at
4°C overnight. Incubations with the same host species IgG served
as negative controls. Sections were washed with Tris-buffered
saline, and the antibody-antigen reaction was detected by in-
cubation with donkey anti-rabbit Alexa Fluor 488-green and/or
donkey anti-mouse Alexa Fluor 568-red diluted 1:500 in Tris-
buffered saline for 1 hour at room temperature. Following
washing with Tris-buffered saline, nuclei were visualized using
DAPI (5 nM; Dako) incubated for 5 minutes and mounted with
Dako mounting medium.
Western blotting for LAT2 in MVM
Western blotting was performed to conﬁrm expression of LAT2
and its associated heavy chain CD98 (C-20; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) (33) in MVM vesicles. Vesicles
(40 mg protein) were electrophoresed under reducing and
nonreducing, nonboil conditions (8 M urea, 5% SDS, 0.4% bro-
mophenol blue, 455 mM DTT, and 50 mM Tris-HCl, pH 6.9)
using 3% stacking and 10% resolving polyacrylamide gels. Pro-
teins were transferred to HyBond ECL nitrocellulose mem-
branes. Membranes were blocked using 5% nonfat dried milk
(Marvel) diluted in Tris-buffered saline-T (10 mM Tris-HCl,
150mMNaCl, and 0.05%Tween-20, pH 8.0) for 1 hour, followed
by incubation with either LAT2 (1 mg/ml) or CD98 (0.5 mg/ml)
diluted in 5% nonfat dried milk in Tris-buffered saline-T for
1 hour at room temperature. Following washing with Tris-buffered
saline-T for 33 5 minutes, membranes were incubated for 1 hour
with horseradish peroxidase-conjugated anti-mouse IgG and
anti-goat IgG secondary antibodies, respectively (Dako) di-
luted 1:2000 in 5% nonfat dried milk in Tris-buffered saline.
Immunoreactivity was detected by ECL (Pierce, Rockford,
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IL, USA). Negative controls were performed by omission
of primary antibody.
Statistics
Statistical analyses were carried out using GraphPad Prism 5.0
(GraphPadSoftware, La Jolla, CA,USA). Between-groupanalyses
were performed using a 2-way repeated-measures ANOVA fol-
lowed by a Bonferroni post hoc test. Peak overshoot (60 seconds)
versus decay (10 minutes) was analyzed using a paired t test.
P , 0.05 was considered statistically signiﬁcant. Data are
presented as means + SEM, with the number of experiments
(n) denoting the number of placentas studied.
RESULTS
Model predictions for [14C]L-serine uptake into
MVM vesicles
Model simulations were generated topredict [14C]L-serine
uptake into MVM vesicles by the 2 hypothesized transport
mechanisms in response to the experimental conditions.
For the mixed transport model (Fig. 2A), the predicted
outcomes for the zero-transexperiments (experiments 1, 2,
and 5) displayed inhibition of the initial rate of [14C]L-
serine uptake in response to increasing external unlabeled
serine concentrations (cis-inhibition) while approaching
the same equilibrium. The addition of intravesicular
L-serine (experiments 3, 4, 4b, 6, and 7) was predicted to
trans-stimulate [14C]L-serine uptake into MVM vesicles in
a concentration-dependent manner, i.e., higher internal
concentrations of unlabeled L-serine led to a higher initial
rate of [14C]L-serine uptake (Fig. 2B, C). Interestingly, the
mixed model predicted that the presence of a high out-
wardly directed L-serine concentration gradient (experi-
ments 4 and 4b) would lead to an initial overshoot of [14C]
L-serine accumulation into MVM vesicles above equilib-
rium concentrations by a dominant fast exchange mech-
anism followed by attenuation to apparent equilibrium
by a slower facilitated transport mechanism (Fig. 2B). For
the obligate exchangemodel (predictions not shown), the
predicted outcomes for zero-trans experiments (experi-
ments 1, 2, and 5) in the absence of exogenous intra-
vesicular L-serine were zero consistent with the concept of
obligate exchange in which amino acids are required at
both sides of the plasmamembrane to confer transport. In
contrast, the addition of internal concentrations of un-
labeled L-serine was predicted to lead to the accumulation
of [14C]L-serine at different equilibrium concentrations,
proportional to the intravesicular concentration added
(Fig. 2C). In contrast, increases in external serine con-
centrations were predicted to decrease the equilibrium
concentration of [14C]L-serine proportionally.
[14C]L-serine uptake into MVM vesicles corresponds
to simulated uptake curves by the mixed
transport model
Fig. 2D–F shows the uptake of [14C]L-serine into MVM
vesicles under the conditions set by the experimental
matrix (Fig. 1C). We observed time-dependent uptake
of [14C]L-serine into MVM vesicles in the absence of
exogenous intravesicular amino acid (experiments 1, 2,
and 5), which is incompatible with the concept of obliga-
tory exchange (Fig. 2D). In these cases, the rate of [14C]L-
serine uptake signiﬁcantly declined in the presence of
extravesicular L-serine, conﬁrming cis-inhibition of a carrier-
mediated process (experiments 2 and 5). In contrast,
addition of intravesicular L-serine signiﬁcantly trans-
stimulated [14C]L-serine uptake in a concentration-
dependent manner (Fig. 2E), conﬁrming that inﬂux of
extravesicular tracer is stimulated by the presence of
intravesicular amino acid (experiment 2 vs. 4, P, 0.05;
experiment 2 vs. 4b, P , 0.001; experiment 3 vs. 4,
P , 0.001; experiment 3 vs.4b, P , 0.001). Notably, the
degree of trans-stimulation depended on both the di-
rection and magnitude of the transmembrane serine
concentration gradient (Fig. 2E, F). These experiments
showed that the presence of a high outwardly directed
transmembrane L-serine gradient led to the rapid accu-
mulation of [14C]L-serine above equilibrium concentra-
tion at 60 s (overshoot curve; experiment 4, 23.9 6 1.9
pmol/mg protein vs. experiment 2, 5.16 0.5 pmol/mg
protein; P , 0.001). Following peak accumulation,
[14C]L-serine uptake subsequently declined with time
reaching apparent equilibrium by 10 minutes (over-
shoot decay; 60 seconds vs. 10 minutes: experiment 4,
P = 0.001; experiment 4b, P , 0.001). Noticeably, the
peak of the overshoot was signiﬁcantly enhanced by
a steeper gradient (experiment 4b; Fig. 2E; P , 0.001
compared with experiments 4 and 2 with nonloaded
vesicles). The overshoot curve was interpreted to repre-
sent [14C]L-serine uptake by an exchange mechanism
coupled with a facilitated transport mechanism (as
predicted by themixed transportmodel). In these cases,
initial uptake of [14C]L-serine occurs primarily by a fast
exchange mechanism driven by the outwardly directed
transmembrane L-serine gradient (overshoot peak).
The subsequent decline in [14C]L-serine uptake be-
tween 60 seconds (peak) and 10minutes was inferred to
represent the (relatively slower) efﬂux of [14C]L-serine
by a facilitated transport mechanism (overshoot decay).
Conversely, the presence of an inwardly directed L-serine
concentration gradient did not elicit overshoot above
equilibrium (Fig. 2D). All uptakes were linear up to
20 seconds (data not shown). The contribution of vesicle
swelling to the overshoot was excluded because changes
in intravesicular volume during the experiment were
negligible (data not shown).
Carrier model ﬁttings to experimental data
The biologic accuracy of the simulated L-serine uptake
curves was determined by ﬁtting the experimental
L-serine uptake data to the obligate exchange model
and mixed transport model (Fig. 3). For each model,
a single set of parameters was ﬁtted. Overall, the ex-
perimental data were in poor agreement with model
predictions for obligatory exchange across all 8 experi-
mental conditions (Fig. 3D–F). To enable exchange
for the zero-trans uptakes (Fig. 3D), the model ﬁtted
a low initial endogenous L-serine concentration inside
the vesicle of 10 mM; however, in doing so, it was only
able to represent experiment 1 adequately while severely
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underpredicting experiments 2 and 5. In addition, the
obligatory model was unable to represent the other ex-
perimental conditions (Fig. 3E, F). An R2 test revealed that
the obligatory model was incapable of representing the
dataanybetter than a straight line through themeanof the
data (R2 =20.099). In contrast, the experimental data for
[14C]L-serine uptake into MVM vesicles displayed good con-
cordance to the simulations for the mixed transport model
across all experimental conditions (Fig. 3A–C; R2 = 0.69).
Most notably, the predicted overshoot of [14C]L-serine
uptake in response to an outwardly directed L-serine
concentration gradient (experiments 4 and 4b) was in-
deed observed experimentally, and closely resembled
the simulated overshoot by the mixed transport model
(Fig. 3B); this was not observed for the obligatory ex-
change model (Fig. 3E). However, the simulated curve
underestimated the experimental equilibrium concen-
trations, most notable in experiment 4b. The relative
mobility of the unbound transporter parameter (h)
was ﬁtted to be 0.16, which implies the rate for facili-
tated transport relative to obligate exchange was slow
at h = 16%.
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Figure 2. Computational simulations for the mixed transport model and corresponding experimental [14C]L-serine uptake data.
Left) Schematic ﬁgure outlining the experimental design for model simulations, showing the imposed direction and magnitude
of the transmembrane L-serine concentration gradients generated to drive uptake of tracer (7.5 mM [14C]L-serine) into MVM
vesicles (depicted as green circles). A–C) Computational simulations (with h set at 4%) for experiments 1, 2, and 5; experiments
2–4 and 4b; and experiments 5–7 of the experimental test matrix with varying substrate conditions (external: internal unlabeled
L-serine concentration in micromolar). A) In the absence of added intravesicular L-serine to drive exchange, [14C]L-serine uptake
was predicted to occur by facilitated transport as there is no added opposing amino acid to drive exchange (experiment 1).
However, increases in the external L-serine concentration were predicted to decrease [14C]L-serine uptake in a concentration-
dependent manner because of cis-inhibition (experiments 2 and 5). B) In contrast, the addition of L-serine inside the vesicles was
predicted to trans-stimulate [14C]L-serine uptake (experiments 3, 4, and 4b). Interestingly, the outwardly directed concentration
gradient in experiments 4 and 4b was predicted to lead to an overshoot curve (transient accumulation of [14C]L-serine above
ﬁnal equilibrium concentration). C) High extravesicular L-serine concentrations were predicted to reduce L-serine equilibrium
concentrations compared with experiments 2, 3, and 4 because of cis-inhibition. D–F) Experimentally measured Na+-independent
uptake of 7.5 mM [14C]L-serine into human placental MVM vesicles unloaded or preloaded with L-serine closely resembled the model
simulations shown in A–C (note the difference in axis scales). Symbol numbers relate to experimental condition given by the
experimental matrix. Data are shown as means + SEM (n = 5–9 placentas).
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Trans-stimulation of [14C]L-serine uptake by a broad
variety of intravesicular amino acids
We determined the intravesicular amino acid selectivity
of amino acid exchange transporters by comparing the
trans-stimulation of [14C]L-serine uptake induced by vari-
ous amino acids preloaded intoMVMvesicles. Fig. 4 shows
the inﬂuence of a high outwardly directed substrate con-
centration gradient on the Na+-independent uptake of
[14C]L-serine into MVM vesicles by various neutral amino
acids and analogs. Preloading with 1000 mM L-serine,
L-alanine, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid
(BCH), glycine, L-methionine, D-leucine, L-leucine, and
L-phenylalanine, all known substrates of the system L
transport system, resulted in the substantial and differen-
tial trans-stimulation of [14C]L-serine uptake above equi-
librium concentration (overshoot at 60 seconds), followed
by subsequent reduction with time (Fig. 4A), consistent
with model predictions for the mixed transport model
(Fig. 2B). Surprisingly, L-proline and MeAIB, both sub-
strates of the Na+-dependent system A accumulative
transporters, were similarly effective at stimulating [14C]L-
serine uptake intoMVM vesicles, whereas in contrast, they
did not elicit loss of tracer with time (Fig. 4B). Hence,
varying the intravesicular amino acid availability affects not
only the magnitude of L-serine inﬂux but also exchange
capacity. Interestingly, none of the tested amino acids
demonstrated a higher trans-stimulation than L-serine
(sixfold increase in uptake), and likewise, the highest
degree of trans-stimulation was seen for LAT2 speciﬁc
substrates (L-serine, glycine, and L-alanine). With the
exception of L-leucine, L-methionine, L-proline, and
MeAIB, all uptakes were linear up to 15 seconds (data
not shown).
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Figure 3. Carrier model ﬁttings to experimental data demonstrate that L-serine uptake is best described by the mixed transport
model and not by obligate exchange (A–F). The experimental data were converted to concentration (micromolar) based on an
intravesicular volume of 1.3 ml/mg protein and ﬁtted to the carrier models. Fittings for the mixed model (A–C) and obligate
exchange model (D–F) are shown as solid and dashed lines for the various experimental conditions. Symbol numbers relate
to experimental condition given by the experimental test matrix with L-serine concentrations in parentheses shown as
(extravesicular: intravesicular; in micromolar), respectively. Data are means + SEM (n = 5–9 placentas).
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Endogenous amino acids are present in MVM
vesicle isolates
Amino acids were found to be present in MVM vesicle
isolates and are shown in order of decreasing concentra-
tion (Fig. 5). The relative concentration of amino acids
found in MVM isolates follows a similar pattern and rank-
ing to previous estimates of free intracellular amino acid
concentrations in human placental tissue (34). However,
the proportionality of amino acid concentrations found
in MVM vesicle isolates to reported placental tissue
concentrations was variable across different amino acids
(Fig. 5, upper).
The potential impact of the measured endogenous
amino acid concentrations on the model predictions was
evaluated by repeating the model ﬁts as in Fig. 3, but with
an additional 300mMof substrate in the vesicle suspension
reﬂecting totalLAT2 substrate concentrations (Fig. 5), and
applying the appropriate dilutions of external concen-
trations for each experiment (results not shown). As be-
fore, the obligatory exchange model could not represent
the experimental data (R2 =20.14). Notably for the non-
obligatory transport model, trans-stimulation due to addi-
tional endogenous substrate led to an overshoot for the
nominally zero-trans case (experiment 1). In addition, the
results displayed a signiﬁcant underprediction of initial
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Figure 4. A high outwardly directed substrate concentration gradient imposed by various intravesicular system L amino acid
substrates shows trans-stimulation of [14C]L-serine uptake resulting in overshoot phenomena. A) Various system L amino acid
substrates or analogs were preloaded during vesiculation into MVM vesicles, and [14C]L-serine uptake was measured by
incubation in Na+-free extravesicular buffer compared with nonloaded (NL) vesicles. B) To control for nonselective uptake
effects, L-proline, MeAIB, and the osmotic control mannitol were also included. Data are means + SEM (n = 4–9 placentas).
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Figure 5. Endogenous amino acid concentrations
in human placental MVM vesicle isolates. Amino
acid concentrations in MVM vesicle isolates are
shown in order of diminishing concentration. The
relative ratio (as percentage) of amino acid concen-
tration in MVM vesicle isolates to that reported
previously in placental tissue is shown in the upper
graph (34). Data are shown as means 6 SEM (n = 4
placentas).
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rates and time delays in the peak of the overshoot, and
overall ﬁt quality was reduced (R2 = 0.49). This lack of
correspondence to the experimental data indicates that
not all of themeasuredendogenous substratemaybe freely
exchangeable.
Colocalization of system L transporters LAT1
and LAT2
Fig. 6A–C shows the expression of the L-type amino acid
transporters in human placental villi. Both LAT1 and
LAT2 transport proteins were expressed on the maternal-
facing MVM and fetal-facing basal plasma membrane
(BM)of theplacental epithelial transport barrier, the SCT.
Staining showed a variable pattern with evidence for
colocalization for LAT1 and LAT2 within both plasma
membranes. Relatively minor diffuse foci were also obser-
ved throughout the SCT. Staining was absent in matched
isotype negative controls (Fig. 6D, E).
LAT2 is expressed in MVM of human placenta
Thepresenceof theLAT2protein in the (maternal-facing)
MVM of the human placenta, linked to CD98, was
conﬁrmed by Western blotting (Fig. 6F). Under non-
reducing conditions, both LAT2 and CD98 antibodies
demonstrated immunoreactive species that comigrated at
;155kDa.However, amobility shift from155(CD98-LAT2
heterodimer) to ;40 (LAT2 monomer) and ;80 kDa
(CD98 glycoprotein) was observed under reducing con-
ditions, respectively, thus validating the antibody speciﬁcity
for the LAT2 protein. These bands were not present in the
negative controls (omission of primary antibody).
DISCUSSION
This study presents a novel integrated approach that
combines computational modeling with membrane trans-
port studies to investigate the underlying mechanisms of
amino acid exchange transporters. Our studies reveal that
exchangers, believed to be obligatory, may exhibit other
patterns of transport behavior relating to facilitated trans-
port. This conclusion is inferred from the observation
that the computational model could only account for the
uptake of L-serine into MVM vesicles when the transporter
didnot functionexclusively in exchangemode. Importantly,
this delineation could not have been derived without com-
putational simulation, which anticipated distinct differences
**
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CD98 LAT2
NRR NRR
155
75
40
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Figure 6. Immunolocalization of LAT2 to the MVM of human placental SCT and colocalization with LAT1. A–C) The L-type
amino acid transport proteins LAT1 (green) and LAT2 (red) were expressed in both the maternal-facing MVM and fetal-facing
BM of the human placental SCT, showing areas of colocalization (orange, arrows). However, the membrane distribution of the
two proteins varied, such that LAT1 appeared to be more strongly associated with the MVM (white dotted line) compared with
the BM (yellow dotted line), whereas in contrast, LAT2 appeared to be strongly expressed throughout both plasma membranes;
LAT2 positivity was also observed within the fetal endothelium (asterisks). Relatively minor diffuse staining was seen in the SCT
for both proteins. Staining was absent in matched isotype negative controls for LAT1 (D) and LAT2 (E). Blue = DAPI. Final
magniﬁcation, 3630. F) Western blotting for LAT2 and its associated heavy chain CD98 in MVM membranes from term human
placenta. Under nonreducing conditions (NR), LAT2 and CD98 antibodies showed immunoreactive species at ;155 kDa, which
were absent from the negative controls (2ve). Under reducing conditions (R), the ;155 kDa LAT2-CD98 heterodimer was
reduced to either an ;40 kDa (LAT2) or ;80 kDa (CD98) band. The observed mobility shift (9) thus conﬁrms antibody
speciﬁcity for the LAT2 protein in human placental MVM.
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in L-serine transport depending on the degree of exchange
obligation. The integration of computational simulation
and experimental validation has therefore led to new
quantitative insights into amino acid exchange transport
mechanisms, which could not have been derived from
experimentation alone.
As demonstrated, the principal strength of the model
was the ability to distinguish and capture the main mech-
anisms of L-serine transport across a range of experimental
conditions, using only a minimum number of parameters.
Signiﬁcantly, the model accounted for the different
transport mechanisms by varying the mobility of an
unloaded transporter, and its predicted effect on tracer
accumulation in response to differing concentrations of
amino acids at both sides of the plasma membrane. To
facilitate biologic interpretation and the estimation of
a unique set ofmodel parameters, the transport properties
were assumed to be symmetric across the plasma mem-
brane. However, this is not an intrinsic limitation of the
transport model, and the introduction of additional
parameters may improve representation (19).
In keeping with our initial modeling paradigms (19),
L-serine was selected as the experimental amino acid sub-
strate to test the carrier model. L-serine is transported
primarily with relatively high afﬁnity by the system L
transporter LAT2 and not by LAT1 (10, 11, 15, 16, 18). We
therefore propose that our model describes the transport
mechanism of the LAT2 transporter. Although substrate
inhibition studies have evidenced LAT2 transport activity
in human placental MVM, we demonstrate for the ﬁrst
time theexpressionof theLAT2protein in thismembrane,
supporting LAT2mediated L-serine transport (16, 26, 35).
This is a novel ﬁnding because LAT1 was thought to be
polarized to the MVM (36), whereas LAT2 was suggested
to be the dominant system L isoform on the opposing BM
of SCT (24). The colocalization of bothLAT1 andLAT2 to
both SCT plasma membranes therefore suggests that
the distribution of these proteins may not be as highly
polarized as in other epithelia (6, 9, 37) and that they may
work in concert to mediate transplacental amino acid
transport.
The agreement of the experimental data to the mixed
transport model (in comparison to the obligate exchange
model) provides conﬁdence that this is a reliable mecha-
nistic framework to describe LAT2-mediated transport
across MVM. This is an important ﬁnding as there is
reported heterogeneity in terms of its obligatory nature.
Although Sewaga et al. were unable to trans-stimulate
L-leucine efﬂux from preinjected Xenopus oocytes trans-
fected with LAT2 inferring facilitated transport (18), oth-
ers demonstrate trans-stimulation of amino acid uptake
into preinjected Xenopus oocytes transfected with LAT2,
interpreted to represent obligate exchange (9, 15, 18).
Consistent with the latter, we show that preloading vesicles
with L-serine leads to higher intravesicular concentrations
of [14C]L-serine above nonloaded controls, demonstrating
that transport can be trans-stimulated. Although this has
typically been interpreted as evidence for exchange, it
must be borne in mind that a facilitated transporter can
also display trans-stimulation (i.e., faster return of the car-
rier because of the mediated efﬂux of intravesicular sub-
strate, leading to accelerated uptake by speeding up the
transport cycle; Fig. 1B).
The key factor in determining the contribution of a fa-
cilitated transport component was the computational
simulation for experiment 4b. Themixed transportmodel
predicted that a high outwardly directed L-serine concen-
tration gradient would elicit overshoot curve; this was not
predicted to occur if exchange was fully obligatory. An
overshoot curvewas subsequently observedexperimentally
and was similar to the simulated substrate curve with re-
spect to peak height. Overshoot phenomena are reported
in other transport systems (38); however, little is known
regarding the relationship between the shape of the curve
and the characteristics of the underlying transport mech-
anisms. Computational simulation has therefore driven
us to explore these phenomena further, and we interpret
the overshoot curve to represent initial uptake by a rapid
exchange mechanism (overshoot peak) followed by a de-
cline in uptake (or alternatively increased tracer efﬂux)
mediated by a (slower) facilitated transport component
(overshoot decay). This is because in the absence of a facil-
itated transport route, L-serine would continue to accumu-
late until reaching a constant concentration determined
by the original intracellular amino acid concentration,
which was not observed. However, it is important to note
that, although facilitated transportmay play a role driven by
imposed substrate gradients, the dominant mechanism re-
lating to system L-mediated transport is exchange. What
mechanism dominates in vivo will depend on the trans-
membrane gradients present, e.g., as long as counter
gradients are maintained, then exchange will result in
sustained faster uptake.
The overshoot phenomenon was further conﬁrmed
by a variety of internalized system L substrates (L-alanine,
L-methionine, glycine, D-leucine, L-leucine, and L-phenyl-
alanine). The varying magnitude of the overshoot peaks
suggests that the identity of the intracellular amino acid
modulates the capacity for L-serine trans-stimulation. This
supports previous studies illustrating selectivity of ex-
change by internalized amino acids. For example,
L-phenylalanine is an effective substrate for L-tryptophan
inﬂux (21), whereas we show that L-phenylalanine is a
relatively poor substrate for L-serine inﬂux. This suggests
asymmetry for exchange and agrees with previous studies
showing that inﬂux and efﬂux substrate selectivity may
not be matched. However, of particular interest was the
observation that different internalized systemL substrates
led to different internal concentrations of L-serine at
equilibrium. The reasons for this variability cannot be
fully explained at present. However, it does suggest the
presence of an unknown parameter mediating this
selectivity and may provide one explanation for the under-
estimation of the experimental serine equilibrium con-
centrations by the mixed transport model. Interestingly,
certain internalized amino acids behaved rather un-
expectedly. Both L-proline and MeAIB, classic substrates
of theNa+-dependent systemA transporters butnot system
L (18, 21, 39, 40), signiﬁcantly stimulated [14C]L-serine
inﬂux above nonloaded controls (yet lacked overshoot
seen with classic LAT2 substrates). The mechanisms
underlying this isunclear; however, a contributionbyother
transporters cannot be excluded. Furthermore, internal
BCH, an amino acid analog typically used to study system
L-mediated transport (extracellular BCH inhibits up-
take of system L substrates) (16, 26, 41) also stimulated
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[14C]L-serine inﬂux. This indicates that BCH is not only an
inhibitor but that it is also an effective substrate for systemL
transporters, as previously demonstrated (21, 42).
The ability of a range of amino acids to elicit overshoot
suggests a commonmechanismmediating the transport of
L-serine across the MVM. We believe this to be a mecha-
nism that shows characteristics of LAT2-mediated trans-
port, and as indicated by the carrier model ﬁttings, one
that displays characteristics of both antiport and uniport
mechanisms. If the apparent exchange associated with
LAT2 becomes less tightly coupled, then exodus of intra-
vesicular amino acid can occur without concomitant up-
take of another amino acid. Such slippage (uncoupled
translocator) has been reported for other antiport systems
that also allow low levels of uniport function (43, 44). It is
possible that slippage represents a function of carrier
protein biochemistry that may constitute a physiologic
mechanism (44–46), although it is not immediately clear
at present what the physiologic relevance of this might be.
On the other hand, we cannot fully exclude the existence
of an additional (kinetically similar) facilitated L-serine
transporter in parallel, although there are no known
reports of these transporters on the MVM of human pla-
centa at present. This emphasizes the need to investigate
the functional role of these transporters as part of a wider
physiologically integrated transport system.
Consistent with previous observations (16), L-serine was
transported into MVM vesicles in the absence of trans-
amino acid, raising the question of how we observe system
L activity in the absence of added intravesicular amino
acid. We show that zero-trans uptake may, in part, be
explained by the presence of endogenous amino acids
found within MVM vesicle isolates that, provided they are
freely exchangeable,maybe sufﬁcient to initiate exchange.
However, our model shows that the experimental data
cannot be explained by perfectly obligatory exchange
driven by endogenous substrate, whether their concen-
trations were low or high (Fig. 3D). Furthermore, their
collective concentrations (in particular for the system L
substrates) were much lower than those determined to
drive maximal transporter activation (e.g., overshoot), as
set by our experimental conditions. The origin of the
observed endogenous amino acids is not clear; however,
their relative concentrations follow a similar ranking to
previous estimates of free intracellular amino acid con-
centrations in human placental tissue (34), suggesting
some degree of procedural carryover. Moreover, whether
the measured concentrations of endogenous amino acids
in vitro are a reliable representation of concentrations at
the ﬂuid tissue interface in vivo is uncertain. Unstirred
layers at the membrane surface of the MVM may lead to
concentration gradients within the glycocalyx such that
concentrations of solutes are different to that in the bulk
solution. However, although potentially affecting kinetic
parameters, it does not alter our ﬁndings in relation to the
transport mechanism.
In summary, our ﬁndings suggest that exchange and
facilitated transporters are 2 ends of a spectrum and that
where they are placed on this spectrum is determined
by the speed of return of the unloaded carrier. The in-
tegration of computational modeling with amino acid
transport studies has therefore generatednewmechanistic
insights into the different modes of amino acid transport.
Modeling has allowed us to predict how transporters
should act based on our understanding, to design experi-
ments that will speciﬁcally test our understanding, and to
interpret the results of these experiments. An iterative cy-
cle of model predications, experimental validation, and
model reﬁnement will therefore lead to an improved
quantitative understanding of the interactive mechanisms
underlying amino acid transfer as a biologic system in both
health and disease.
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